Physician profile
Michael E Saridakis
NPI 1164462875
$5,643.81
in general payments reported to CMS, 2019-2025
38 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,806 · 2020: $1,891 · 2021: $79.42 · 2022: $795 · 2023: $387 · 2024: $134 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $677.12 | 2019-2020 | |
| Novo Nordisk INC | $543.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $462.82 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $431.71 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $420.48 | 2022 | |
| Pfizer INC. | $356.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $309.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $296.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.04 | 2022-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $228.60 | 2019-2024 | Xarelto |
| Abbvie INC. | $189.12 | 2019-2025 | |
| Amarin Pharma, INC. | $122.30 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $109.46 | 2019-2020 | |
| Astellas Pharma US INC | $107.17 | 2019-2025 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Saridakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.